Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICE Trial: Nicotinamide Riboside With and Without Resveratrol in PAD
NCT03743636Phase 3Completed
- Sponsor
- Northwestern University
- Start
- Oct 2018
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral artery disease (PAD) comparing Nicotinamide riboside + resveratrol, Nicotinamide riboside + placebo and Placebo + placebo (3 arms). Primary endpoint: Six-minute Walk Distance at 6 months. Started Oct 2018; status: completed.
02
Drugs
nicotinamide riboside
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT03743636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743636.